J&J multiple myeloma drug Talvey cuts mortality risk (JNJ:NYSE)
· seekingalpha.com
Johnson & Johnson (JNJ) stock is in focus as trial data show the company's multiple myeloma drug Talvey's potential in an earlier line setting. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...